Craig N Zimmerman

USPTO Granted Patents = 36 (Patent Applications = 5)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 4.9

ph-index = 13

Forward Citations = 663(Granted Patents)

Location History:

Somerville, MA (US) (2001 - 2006)
Cambridge, MA (US) (2013 - 2020)
Topsfield, MA (US) (2001 - 2023)

Company Filing History:

24 out of 40

Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticlas, Inc.

Ironwood Pharmaceuticals, Inc.

patents

Years Active: 2001-2023

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11712485 - Triazine based radiopharmaceuticals and radioimaging agents (2023-08-01),

2. 10898598 - Triazine based radiopharmaceuticals and radioimaging agents (2021-01-26),

3. 10647666 - Heterodimers of glutamic acid (2020-05-12),

4. 10640461 - Heterodimers of glutamic acid (2020-05-05),

5. 10201624 - Triazine based radiopharmaceuticals and radioimaging agents (2019-02-12),

6. 10131627 - Heterodimers of glutamic acid (2018-11-20),

7. 10086096 - Triazine based radiopharmaceuticals and radioimaging agents (2018-10-02),

8. 9878980 - Heterodimers of glutamic acid (2018-01-30),

9. 9687572 - PSMA-targeted dendrimers (2017-06-27),

10. 9447121 - Triazine based radiopharmaceuticals and radioimaging agents (2016-09-20),

11. 9433594 - Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof (2016-09-06),

12. 9422251 - Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX (2016-08-23),

13. 9388144 - Radiolabeled prostate specific membrane antigen inhibitors (2016-07-12),

14. 9309193 - Heterodimers of glutamic acid (2016-04-12),

15. 9149547 - Process for production of heterodimers of glutamic acid (2015-10-06),

Title: Innovations of Craig N. Zimmerman in Radiopharmaceuticals

Introduction

Craig N. Zimmerman, based in Cambridge, Massachusetts, is a distinguished inventor with an impressive portfolio of 36 patents. His work primarily focuses on advancements in radiopharmaceuticals, contributing to significant innovations in medical imaging and therapies.

Latest Patents

Among his latest patented innovations are "Triazine based radiopharmaceuticals and radioimaging agents," which highlight the development of metal complexes that include a radionuclide, along with compounds denoted as Formula I and Formula II. These innovations serve as potent inhibitors of the Prostate-Specific Membrane Antigen (PSMA), showcasing Zimmerman's commitment to enhancing the field of nuclear medicine.

Career Highlights

Craig has made notable contributions while working at companies such as Molecular Insight Pharmaceuticals, Inc. and Biogen, Incorporated. His tenure at these organizations has enriched his expertise and has propelled his innovations forward, further solidifying his position in the field of biopharmaceutical development.

Collaborations

Throughout his career, Zimmerman has collaborated with prominent individuals in the industry, including John W. Babich and John L. Joyal. These collaborations have allowed for a fusion of ideas, leading to the successful development of impactful medical solutions.

Conclusion

Craig N. Zimmerman's contributions to the field of radiopharmaceuticals are significant and continue to evolve. With a wealth of patents and a strong collaborative network, he remains a key figure in driving innovations that improve medical imaging and treatment options. As the industry advances, his work will undoubtedly contribute to further breakthroughs in healthcare technologies.

This text is generated by artificial intelligence and may not be accurate.